Holger Zimmermann, PhD

Chief Research & Development Officer at AiCuris Anti-infective Cures

Speaker

Holger was part of the spin-out which formed AiCuris in 2006. He is an inventor of Letermovir and was responsible for the development of the drug (out-licensed to MSD in 2012) before taking over responsibility for all AiCuris’ research activities as Chief Scientific Officer. After two years as the company’s managing director and deputy CEO and 6 years as its CSO Holger took over responsibility as CEO of AiCuris in 2015. In 2023 he took over the role of Chief Research and Development Officer focusing on all research, development and CMC activities in the newly formed executive board of the AiCuris Anti-infective Cures AG.

Prior to AiCuris, Holger worked at Bayer Health Care as laboratory head and project leader in virology. He obtained his PhD in Biology in Cologne and worked overall seven years in academic institutions, including three years at the Institute of Molecular and Cell Biology (IMCB) of the National University of Singapore.

Holger is author/co-author of numerous scientific publications and named inventor in more than 25 patent applications. He is member of national and international scientific societies and serves on several boards including those of: International Society on Antiviral Research, German Society of Virology (GfV) - Committee on Antiviral Therapy, Member of the Board of BioRiver, Member of the Executive Board of Bio Deutschland